The antiemetic agent Aloxi™ (palonosetron hydrochloride) has recently been incorporated into the 2004 National Comprehensive Cancer Network® (NCCN®) guidelines for the prevention of chemotherapy-induced nausea and vomiting (CINV) following chemotherapy that is moderately or highly associated with nausea and vomiting.1
The NCCN consists of a panel from the nation’s most reputable cancer treatment facilities. The panel sets clinical guidelines that are continually refined and include algorithms for diagnostic procedures and treatment of cancer. NCCN Clinical Practice Guidelines in Oncology are widely recognized and used as the standard for clinical policy in cancer care. The NCCN Complete Library of Clinical Practice Guidelines in Oncology is the only comprehensive set of guidelines updated annually by any national organization in any area of medicine. These guidelines represent the integration of best available scientific evidence and expert opinion in a consensus approach involving thought leaders from medical, surgical and radiation oncology and other pertinent clinical areas. The NCCN guidelines are distributed free of charge to clinical professionals in the United States and internationally. User-friendly patient versions of NCCN guidelines are available to patients and their families. The 2004 guidelines will be made available on the NCCN Web site in the coming weeks, and can be found at www.nccn.com.
Nausea and vomiting are common side effects of chemotherapy treatment. When severe, nausea and vomiting can cause dehydration, complete loss of appetite, and disturbances in electrolytes and nutritional management. Dosing and/or scheduling of chemotherapy treatments may be affected due to severe nausea and vomiting, ultimately resulting in the delivery of suboptimal regimens. Therefore, the prevention and/or reduction or reducing chemotherapy-induced nausea and vomiting is of important consideration and researchers are continuing to develop and evaluate novel agents to address this issue. Nausea and vomiting are typically managed with one or several conventional agents called antiemetics. Often, physicians will use combinations of antiemetics with different modes of action for either the prevention and/or treatment of chemotherapy induced nausea and vomiting. Aloxi™ is an antiemetic that belongs to a class of agents referred to as 5-HT(3) receptor antagonists. Aloxi™ is currently approved by the FDA for the prevention of acute or delayed nausea and vomiting associated with initial and repeat courses of chemotherapy that is moderately or highly associated with nausea and vomiting.2
NCCN recently identified Aloxi™ as the “preferred” agent for the prevention of CINV following chemotherapy that is moderately associated with causing nausea and vomiting. In addition, Aloxi™ injection is recommended by the NCCN for administration on the first day of treatment to protect patients receiving chemotherapy that is highly associated with causing nausea and vomiting. Chemotherapy agents categorized in level 3, 4, and 5 are defined as causing a 30-90% frequency of vomiting, and are commonly used to treat breast cancer, ovarian cancer, colorectal cancer and lung cancer.Patients who are to receive chemotherapy that may be associated with nausea and vomiting may wish to speak with their physician about the risks and benefits of Aloxi™.
- Aloxi injection incorporated into NCCN guidelines. Available at: www.corporate-ir.net/ireye/ir_site.zhtml?ticker=MOGN&script=410&layout=6&item_id=504255. Accessed March 29, 2004.
- Aloxi. Palonosetron HCL injection. Available at: www.Aloxi.com. Accessed March, 2004.
Copyright © 2018 CancerConnect. All Rights Reserved.